12:00 AM
May 20, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

LX4211 tablet: Phase II ongoing

Lexicon began the double-blind, placebo-controlled expansion portion of a U.S. Phase II trial of once-daily, oral LX4211 in Type I diabetics. The portion will evaluate 400 mg LX4211 for 29 days in up to 30...

Read the full 152 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >